Earnings Summary

Mirum Pharmaceuticals Inc’s revenue jumped 89.37% since last year same period to $90.38Mn in the Q3 2024. On a quarterly growth basis, Mirum Pharmaceuticals Inc has generated 16.05% jump in its revenue since last 3-months.

Mirum Pharmaceuticals Inc’s net profit jumped 39.65% since last year same period to $-14.24Mn in the Q3 2024. On a quarterly growth basis, Mirum Pharmaceuticals Inc has generated 42.22% jump in its net profits since last 3-months.

Mirum Pharmaceuticals Inc’s net profit margin jumped 68.13% since last year same period to -15.75% in the Q3 2024. On a quarterly growth basis, Mirum Pharmaceuticals Inc has generated 50.22% jump in its net profit margins since last 3-months.

Mirum Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.48.

Mirum Pharmaceuticals Inc’s earning per share (EPS) jumped 47.74% since last year same period to -0.3 in the Q3 2024. This indicates that the Mirum Pharmaceuticals Inc has generated 47.74% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mirum Pharmaceuticals Inc’s return on assets (ROA) stands at -0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mirum Pharmaceuticals Inc’s return on equity (ROE) stands at -0.4.